Allied Market Research published a report, titled, "Cytogenetics Market by Product (Consumable, Instrument, Software and Service), by Technique (Comparative Genome Hybridization, Fluorescence in Situ ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

Molecular Instruments® (MI), founded by the inventor of the HCR™ technology, today announces the launch of the HCR™ Gold and ...

The "Bladder Cancer Diagnostics Market by Test Type, by Stages, by Cancer Type, by End User, and By Region" report has been ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

All positive (IHC 3+) and doubtful (IHC 2+) cases were screened by fl uorescence in situ hybridization (FISH). Patients with HER2 gene amplification, normal left ventricular ejection fraction ...

Companion Cancer Diagnostics Market The rising incidence of cancer worldwide is a primary driver of the Global Companion Cancer Diagnostics ...

The researchers also noted that patients with IHC 2+ and in situ hybridization-amplified disease derived less benefit from T-DM1 compared to the IHC 3+ population, suggesting a need for more ...

This study provides a valuable new resource to investigate the molecular basis of the particular features characterizing the pipefish embryo. The authors found both unique and shared gene expression ...